Best health care tips on the net


Important Issues in Pharmaceutical Industry

Many of the strongest European pharmaceuticala substantial equity position in Biogen, a
firms adopted this strategy, seeking topractice that became increasingly popular in
develop their own capabilities across apharmaceuticals. The situation with Biogen
relatively narrow front while working withand Schering-Plough illustrates the finding
biotech startups. The small,of study conducted by Lerner and Merger
university-linked biotechs were at first(1998), which identified 25 critical control
almost entirely an American phenomenon, andrights in biotechnology innovation alliances,
this gave the large U.S. pharmaceuticalin particular those regarding alliance
companies an initial advantage, as did themanagement (manufacturing, clinical trials),
federal government's support for basicthe control of intellectual property,
research in molecular genetics. But soon,determination of alliance scope, equity in
European governments were attempting to closeR&D  companies,  seats  in companies' boards.
the widening biotech gap, hoping that
government support would make up for theFrom standpoint of human resource management,
venture capital that was not available toinnovation in pharmaceutical industry in the
their  potential  innovators.light of all accompanied trends inevitably
leads to outsourcing of labor (not associated
One of the interesting international hybridswith acquisitions or mergers). During
was Biogen, a startup that was built on1999-2004, pharmaceutical firms increased the
American science and that quickly expandedextent to which they outsourced R&D
through licensing arrangements with severalsignificantly. Developing economies of India,
leading pharmaceutical firms. Biogen soon hadChina and Singapore now play active roles in
operations in Germany, Switzerland, andthe industry, creating not only lower-cost
Belgium. Schering-Plough, an Americansources of assistance but also potential
pharmaceutical company, collaborated withfuture rivals for the large pharmaceutical
Biogen in the race to capture the anticipatedcompanies. From the strategic point of view,
global markets for interferon. To enhance andany company's planning effort must answer the
protect its access to Biogen's products andquestion of how this trend toward outsourcing
processes, Schering-Plough in the end boughtwill impact the industry in future.



1 A B C D E 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 91 92 93 94 95 96 98 99 100 101 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119